|
Maya's Biotech Briefing
Vertex’s $10 billion Crinetics deal signals biotech M&A momentum, while J&J keeps leaning toward smaller acquisitions and Bayer spotlights 15 women entrepreneurs.
The top 9 stories from Mon Jul 6, 2026 06:57 AM to Tue Jul 7, 2026 06:58 AM
Generated July 7, 2026 at 6:58 AM
|
|
|
#1 Novartis agreed to acquire London based Myricx Bio today for $1.1B up front and up to $400M in milestones. As Myricx's CEO tells us today at the company's HQ, this is all about novel ADC payloads Published 2026-07-06 Novartis agreed to acquire London-based Myricx Bio for $1.1 billion upfront and up to $400 million in milestones, with CEO Mohit Rawat citing scientific rationale for NMTi ADC payloads. Covered by: biotechtv.com, insights.citeline.com, endpoints.news, biospace.com, biocentury.com, biocentury.com |
#2 J&J’s Deal Focus: Smaller, Earlier-Stage Deals With Few Large Acquisitions Published 2026-07-06 Johnson & Johnson’s latest reported acquisition is the $1 billion purchase of Firefly Bio. Covered by: insights.citeline.com |
#3 Inside AbbVie’s Biology-First ADC Strategy Published 2026-07-07 AbbVie is building a large oncology antibody-drug conjugate pipeline and pursuing a strategy focused on matching treatments to patient biology. Covered by: insights.citeline.com |
#4 Roche aims to bolster breast cancer pipeline with early-stage Astex deal Published 2026-07-06 Roche’s subsidiary Genentech agreed with Astex, an Otsuka unit, on an early-stage breast cancer collaboration with a $25 million upfront payment. Covered by: endpoints.news, insights.citeline.com |
#5 Apogee details path to $10.9B AbbVie deal; UK starts drug pricing pilot Published 2026-07-06 AbbVie reportedly agreed to acquire Apogee Therapeutics for $10.9 billion after years of discussions, and the UK began a drug pricing pilot. Covered by: endpoints.news |
#6 Beyond Rare: Nucleic Acid Therapeutics Are Targeting The Cardiovascular Mainstream Published 2026-07-06 Pharmaprojects data indicate more than 30 nucleic acid therapeutics are in clinical development for cardiovascular or cardiometabolic indications. Covered by: insights.citeline.com |
#7 Active Motif Announces Exclusive Global Distribution Agreement with Arima Genomics for Advanced 3D Genomics Solutions Published 2026-07-06 Active Motif announced an exclusive global distribution agreement with Arima Genomics to expand Active Motif’s research genomics portfolio and support Arima’s clinical diagnostics focus. Covered by: prnewswire.com |
#8 STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms Published 2026-07-06 Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, gaining commercial acromegaly drug Palsonify and late-stage congenital adrenal hyperplasia therapy development. Covered by: statnews.com |
#9 Bayer Foundation Women Entrepreneurs Award: From AI Diagnostics to Circular Food Tech, 15 Women Are Transforming Health and Food Systems Worldwide Published 2026-07-07 On July 7, 2026, the Bayer Foundation Women Entrepreneurs Award selected 15 women from Latin America, Africa, and Asia for work addressing global healthcare and food security. Covered by: prnewswire.com |
